ENZALUTAMIDE

Information current as at: 1 June 2026

PBAC meeting date: November 2024
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Xtandi®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
ASTELLAS PHARMA AUSTRALIA PTY LTD
Condition/indication:
(therapeutic use)
  • Non-metastatic hormone-sensitive prostate cancer (m0HSPC)
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to existing listing (Category 2)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2024 PBAC meeting
Opportunity for consumer comment:
Open 31/07/2024 and close 25/09/2024 (see PBS Website)
PBAC meeting:
Held on 06/11/2024
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – November 2024
Case ID
a930
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19